Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 10 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Navid Zohoury¹, Munther A. Khamashta², Tatsuya Atsumi³, Jacek Musial⁴, Toshiyuki Watanabe⁵, Maria Papp⁶, Concepción González-Rodríguez⁷, Roger Albesa¹, Gary L. Norman¹, Pier-Luigi Meroni⁸ and Michael Mahler¹, ¹Research, INOVA Diagnostics, San Diego, CA, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁴Depment of Medicine, Jagiellonian University Medical College, Krakow, Poland, ⁵Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ⁶MHSCInstitute of Medicine, Department of Gastroenterology, University of Debrecen, Debrecen, Hungary, ⁷University Hospital Virgen Macarena, Sevilla, Spain, ⁸Int Medicine, University of Milan, Milano, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 2404 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus and/or Antiphospholipid Antibody Positive Patients: Two-Year Preliminary Analysis of Diet and Exercise Habits
Virginia Haiduc¹, Monica C. Richey¹, Sotiria Everett², Aeshita Dwivedi¹, Lisa Konstantellis¹, Hassan Ghomrawi³ and Doruk Erkan⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Healthcare Research and Policy, Weill Cornell Medical College, New York, NY, ⁴Rheumatology Dept, Hospital for Special Surgery, New York, NY
Background/Purpose: SLE patients have high rate of cardiovascular events due to increased prevalence of traditional cardiovascular disease (CVD)- and other lupus-related thrombosis risk factors. In…
Abstract Number: 1737 • 2012 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage Caused by Primary Antiphospholipid Syndrome
Rodrigo Cartin-Ceba¹, Tobias Peikert², Karina Keogh², Steven R. Ytterberg³, Aneel Ashrani⁴ and Ulrich Specks², ¹Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Rheumatology Division, Mayo Clinic, Rochester, MN, ⁴Hematology, Mayo Clinic, Rochester, MN
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an uncommon but severe complication of primary antiphospholipid syndrome (APS). The available literature is limited to very few case…
Abstract Number: 1740 • 2012 ACR/ARHP Annual Meeting
Impairment of Quality of Life in Patients with Antiphospholipid Syndrome
Stephane Zuily¹, Francis Guillemin², Veronique Regnault³, Pierre Kaminsky⁴, Patrick Mismetti⁵, Jacques Ninet⁶, Nicolas Baillet⁷, Nadine Magy-Bertrand⁸, Bernard Lorcerie⁹, Jean-Louis Pasquali¹⁰, Thomas Lecompte¹¹, Anne-Christine Rat¹² and Denis Wahl¹³, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, ³Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France, ⁴Internal Medicine, Orphan disease Unit, Nancy, France, ⁵CHU Saint-Etienne, Unité de Pharmacologie Clinique, Groupe de Recherche sur la Thrombose (EA 3065), Saint Etienne, France, ⁶Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ⁷Hôpitaux civils de Colmar, Service de Médecine interne, Colmar, France, ⁸CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, ⁹Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, ¹⁰Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, ¹¹Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹²Université de Lorraine, INSERM, CIC-EC CIE6, Rheumatology, Epidemiology, Nancy, France, ¹³Nancy University Hospital and INSERM U961, Vascular medicine division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, France
Background/Purpose : Quality of life (QoL) is an important outcome in clinical care especially in patients with chronic disease such as systemic lupus erythematosus (SLE).…
Abstract Number: 1724 • 2012 ACR/ARHP Annual Meeting
Pandemic Influenza Immunization in Primary Antiphospholipid Syndrome (PAPS): A Trigger to Autoantibody Production?
Danielle M. Medeiros¹, Cleonice Bueno², Ana Cristina M. Ribeiro¹, Ana L. G. Calich¹, Karina Rossi Bonfiglioli³, Vilma S. Viana¹, Jozelio F. Carvalho⁴, Clovis Artur Silva⁵ and Eloisa Bonfá⁶, ¹Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Divison of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ⁶Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: There are scarce data suggesting that pandemic influenza vaccination may induce antiphospholipid (APL) autoantibodies in inflammatory rheumatic diseases, particularly in systemic lupus erythematosus patients.…
Abstract Number: 1728 • 2012 ACR/ARHP Annual Meeting
Purified IgG From Antiphospholipid Syndrome Patients with Pregnancy Morbidity Alone Inhibit Trophoblast Migration and Activate a TLR4 MyD88 Independent Pathway
Katie Poulton¹, Vera Ripoll¹, Charis Pericleous², Yiannis Ioannou³, Anisur Rahman⁴ and Ian Giles⁴, ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ³Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom
Background/Purpose: Patients with the Antiphospholipid Syndrome (APS) have circulating antiphospholipid antibodies which cause vascular thrombosis (VT) and/or pregnancy morbidity (PM). Previously we have shown that…
Abstract Number: 1733 • 2012 ACR/ARHP Annual Meeting
Effect of Hydroxychloroquine (HCQ) On the Annexin A5 Resistance Assay (AnxA5-RA) in Antiphospholipid Antibody (aPL)-Positive Patients: Preliminary Results of an Ongoing Prospective Study
Alana B. Levine¹, Jacob H. Rand², Xiao Xuan Wu³, JoAnn Vega⁴, Glendalee Ramon¹, Stephen L. Lyman⁴, Doruk Erkan¹ and Michael D. Lockshin⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, ³Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, ⁴Research, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: One proposed mechanism of aPL-mediated thrombosis is disruption of the AnxA5 shield, allowing initiation of coagulation reactions on phospholipid surfaces. The AnxA5-RA measures the…
Abstract Number: 1734 • 2012 ACR/ARHP Annual Meeting
Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities
Savino Sciascia¹, Veronica Murru¹, Giovanni Sanna², Dario Roccatello³, Munther A. Khamashta⁴ and Maria Laura Bertolaccini¹, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: The clinical accuracy of testing for antiphospholipid antibody (aPL) both, as individual tests and/or in combination, is still being investigated. We aimed to identify…
Abstract Number: 1735 • 2012 ACR/ARHP Annual Meeting
Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)
Savino Sciascia¹, Maria Laura Bertolaccini¹, Dario Roccatello² and Munther A. Khamashta³, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ³Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: The so called “antiphospholipid score (aPL-S)” was recently developed and validated (1). This score was shown to be a useful quantitative index for diagnosing…
Abstract Number: 2456 • 2012 ACR/ARHP Annual Meeting
Pro-Inflammatory and Pro-Thrombotic Markers in Persistently Antiphospholipid Antibody-Positive Patients with/without Systemic Lupus Erythematosus
Gurjot Basra¹, Doruk Erkan², Rohan Willis¹, JoAnn Vega³, Ana Laura Carrera Marin⁴, Patricia Ruiz Limon¹, Vijaya L. Murthy¹, Shraddha Jatwani¹, Neha Dang¹, Emilio B. Gonzalez¹ and Silvia S. Pierangeli⁴, ¹Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Research, Hospital for Special Surgery, New York, NY, ⁴Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Pro-inflammatory/thrombotic biomarkers (BMR), which are associated with aPL-mediated pathogenic effects in vitro/vivo, are also increased in aPL-positive patients. Here we examined whether those BMR…
Abstract Number: 2458 • 2012 ACR/ARHP Annual Meeting
The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infarction, and Deep Vein Thrombosis
Laura Andreoli¹, Alessandra Banzato², Cecilia B. Chighizola³, Guillermo J. Pons-Estel⁴, Guilherme Ramires de Jesus⁵, Michael D. Lockshin⁶, Doruk Erkan⁷ and On Behalf of APS Action⁸, ¹Rheumatology and Clinical Immunology, University of Brescia, Brescia, Italy, ²Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ³Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ⁴Servicio de Enfermedades Autoinmunes, Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, ⁵Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸APS ACTION, New York, NY
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international research network that has been created specifically to design and…
Abstract Number: 2459 • 2012 ACR/ARHP Annual Meeting
Efficacy of Aspirin for the Prevention of the First Thrombo-Embolic Events in Patients with Antiphospholipid Antibodies: A Metanalysis of Literature Data
Laurent Arnaud¹, Alexis Mathian², Amelia Ruffatti³, Maria Tecktonidou⁴, Ricard Cervera⁵, Ricardo Forastiero⁶, Vittorio Pengo⁷, Marc Lambert⁸, Stephane Zuily⁹, Denis Wahl⁹ and Zahir Amoura¹, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy, ⁴First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁵Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain, ⁶Favaloro University, Argentina, ⁷Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ⁸Medecine Interne Lilloise, Internal Medicine University Lille Hospital, Lille, Lille, France, ⁹Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital, Université de Lorraine & INSERM U961, Vandoeuvre-Les-Nancy, France
Background/Purpose: Whether aspirin is needed in patients with antiphospholipid antibodies (aPL+) for prevention of a first thrombotic event is controversial. The aim of this metaanalysis…
Abstract Number: 2460 • 2012 ACR/ARHP Annual Meeting
Dual Antiplatelet Therapy As Prophylaxis of Recurrent Arterial Thrombosis in Patients with　antiphospholipid Syndrome
Yuichiro Fujieda¹, Olga Amengual², Toshiyuki Watanabe¹, Michihito Kono², Yusaku Kanetsuka², Takashi Kurita², Toshio Odani¹, Kotaro Otomo¹, Toshiyuki Bohgaki², Tetsuya Horita², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Medicine II, Hokkaido University, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Arterial thrombosis (AT) is a major clinicalmanifestation of the antiphospholipid syndrome (APS). A number of studies have evaluated the rate of recurrent thromboembolism, including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].